Anna Gzik

OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer

P. Dobrzanski, Bartłomiej Borek, K. Dzwonek, 2022, Cancers.

Targeting ARG2 as a novel therapeutic approach for cancer

P. Dobrzanski, Bartłomiej Borek, K. Dzwonek, 2019, Annals of Oncology.

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

D. Nowis, J. Gołąb, A. Sosnowska, 2019, Nature Communications.

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

D. Nowis, J. Gołąb, A. Sosnowska, 2019, Nature Communications.

Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy.

J. Gołąb, P. Dobrzanski, P. Iwanowski, 2023, Molecular cancer therapeutics.